Clinical trials: Coronary Embolism
Other Acute Illnesses Presenting to the Hospital, Heart Failure
Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
This VA QUERI Partnered Evaluation Initiative will evaluate the impact of an immersive Point-of-care Ultrasound (POCUS) Training Course on provider skill acquisition and retention; the frequency of POCUS use by trained providers…
- Conditions
- Other Acute Illnesses Presenting to the Hospital, Heart Failure, Pneumonia, Deep Venous Thrombosis
- Trial name
- NCT03296280
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Pulmonary Embolism, Embolism
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
Evaluate the safety and efficacy of the Aventus Thrombectomy System for aspiration thrombectomy in subjects with acute pulmonary embolism.
- Conditions
- Pulmonary Embolism, Embolism, Embolism and Thrombosis, Vascular Diseases
- Trial name
- NCT05907564
- Testing
- Thrombectomy
- Where
- 26 sites in United States
- Volunteers
- 120 people
- Sponsor
- Inquis Medical, Inc.
Anemia, Hematologic Diseases
Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease
The purpose of this study is to compare liberal red blood cell transfusion therapy with restrictive red blood cell transfusion therapy in surgical patients with cardiovascular disease or risk factors.
- Conditions
- Anemia, Hematologic Diseases, Cardiovascular Diseases, Heart Diseases
- Trial name
- FOCUS (NCT00071032)
- Testing
- Liberal (10 g/dL) Transfusion Strategy, Restrictive (Symptomatic) Transfusion Strategy
- Where
- United States
- Volunteers
- 2,016 people
- Sponsor
- Rutgers, The State University of New Jersey
Prevention of Stroke or Systemic Embolism, Atrial Fibrillation
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
Researchers are looking for a better way to treat people with atrial fibrillation (AF) and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel).
- Trial name
- OCEANIC-AF (NCT05643573)
- Testing
- Asundexian (BAY2433334), Apixaban
- Where
- 1,069 sites in United States, Argentina and 36 more
- Volunteers
- 14,830 people
- Sponsor
- Bayer
Heart Defects, Congenital
Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation
Contemporary management of cyanotic congenital heart disease includes three stages of surgery. Incidence of shunt thrombosis and death between the two first stages of palliation remains important.
- Trial name
- CLARINET (NCT00396877)
- Testing
- Clopidogrel (SR25990)
- Where
- 31 sites in United States, Argentina and 29 more
- Volunteers
- 906 people
- Sponsor
- Sanofi
Pulmonary Embolism, Venous Thromboembolism
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
The researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Atrial Fibrillation
- Trial name
- NCT05351749
- Testing
- New-prescription Alert, New-prescription Alert with referral option, Existing-prescription notification to prescriber
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- University of Michigan
Atrial Fibrillation
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).
- Trial name
- NCT00494871
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- 165 sites in Japan
- Volunteers
- 1,280 people
- Sponsor
- Bayer
Thromboembolism, Heart Valve Prosthesis
Follow on Study From RE-ALIGN
To collect additional data relating to safety and indicators of efficacy for patients who have participated in the 1160.113 study.
- Trial name
- NCT01505881
- Testing
- dabigatran etexilate low dose, warfarin 5mg, dabigatran etexilate intermediate dose
- Where
- 30 sites in Belgium, Canada and 7 more
- Volunteers
- 158 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Deep Vein Thrombosis
Weekly Monitoring Strategy of Capillary INR Versus Monthly Monitoring Strategy of Venous INR in Elderly Patients in a Nursing Home.
This primary care study aims to compare the "time in therapeutic range" (TTR) of two strategies for monitoring the international normalized ratio (INR) over 6 months in nursing homes.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Stroke
- Trial name
- INR-CAP (NCT05561244)
- Testing
- Weekly monitoring using the capillary International Normalised Ratio strategy
- Where
- 33 sites in France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Heart Defects, Congenital
Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation
This study is the extension of the CLARINET study [NCT00396877 -EFC5314] in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt.
- Trial name
- CLARINET LT (NCT00833703)
- Testing
- Clopidogrel
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 49 people
- Sponsor
- Sanofi
Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
The purpose of this study is to examine the degree to which pulmonary embolism (clot) can be dissolved when treated with a very low dose of a systemic thrombolytic drug (clot buster) along with standard anticoagulant therapy as…
- Conditions
- Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive
- Trial name
- SAFE-LYSE (NCT03988842)
- Testing
- Alteplase, Unfractionated heparin, Apixaban
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Victor Tapson, MD
Left Sided Heart Failure, Left Ventricular Assist Device
Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
This study evaluates two different methods for monitoring a patient's anti-clotting [heparin] therapy after they receive a heart pump implant [left ventricular assist device -LVAD].
- Conditions
- Left Sided Heart Failure, Left Ventricular Assist Device, Anticoagulant Therapy, Gastro Intestinal Bleeding
- Trial name
- VAD-ANTIX (NCT03143569)
- Testing
- aPTT guided heparin management, Anti-factor Xa guided heparin management
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Aortic Stenosis, Inflammation
Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)
The central hypothesis of this study is that TAVR leads to platelet deposition and inflammatory cell activation that can be attenuated by the potent anti-platelet and/or pleiotropic effects of ticagrelor.
- Conditions
- Aortic Stenosis, Inflammation, Thrombosis
- Trial name
- NCT02486367
- Testing
- Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University Hospitals Cleveland Medical Center
Thrombosis
Heart and Hands Study II: A Retrospective Data Collection & Analysis Project
A recent pilot study conducted at HealthEast found use of manual pressure with the SoftSeal hemostatic pad for 15 minutes was successful in 9 out of 10 people fully anticoagluated using 4 French radial sheath.
- Trial name
- NCT02307318
- Testing
- SoftSeal Hemostatic Pad
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- HealthEast Care System
Atrial Fibrillation, Thromboembolism
A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF).
- Trial name
- NCT00504556
- Testing
- Edoxaban (DU-176b), warfarin
- Where
- 91 sites in United States, Belarus and 10 more
- Volunteers
- 1,146 people
- Sponsor
- Daiichi Sankyo
Atrial Fibrillation, Thromboembolism
AMPLATZER™ LAA Occluder Post Approval Study (PAS)
The aim of this multicenter, non-randomized observational post-approval is to compile real world outcome data on the use of an AMPLATZER LAA Occluder in subjects with non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Thromboembolism, Stroke
- Trial name
- NCT02964208
- Testing
- AMPLATZER™ LAA Occluder
- Where
- 22 sites in Argentina, Belgium and 5 more
- Volunteers
- 520 people
- Sponsor
- Abbott Medical Devices
Coronary Occlusion, Thrombosis (Stent Thrombosis)
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
This is a prospective, randomized, active-controlled, open label, parallel two-arm, multi-center, post-approval study descriptively comparing the XIENCE V EECSS to the CYPHER SELECT PLUS Sirolimus-Eluting Coronary Stent System…
- Conditions
- Coronary Occlusion, Thrombosis (Stent Thrombosis), Vascular Disease, Myocardial Ischemia
- Trial name
- NCT01178268
- Testing
- XIENCE V EECSS, CYPHER SELECT PLUS SECSS
- Where
- 2 sites in China
- Volunteers
- 546 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Heart Valve Disease
D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement
The optimal intensity of oral anticoagulation in China patients undergoing mechanical valve replacements is still controversial due to the different risk profiles of thrombophilia and bleeding in Chinese patients.
- Trial name
- 3D-INTENSITY (NCT01996657)
- Testing
- Warfarin
- Where
- 2 sites in China
- Volunteers
- 772 people, healthy volunteers welcome
- Sponsor
- Wuhan Asia Heart Hospital
Atrial Fibrillation, Thrombi
Exclusion of Intra-atrial Thrombus Before Catheter Ablation
Atrial fibrillation is the most frequent heart rhythm disorder. Its symptomatic forms, resistant to drug therapy, require invasive management (catheter ablation), which exposes to potentially serious complications including…
- Trial name
- EXTRALUCID (NCT03455673)
- Testing
- ATE score
- Where
- 15 sites in France, Switzerland
- Volunteers
- 3,160 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis